A61K 2039/5258
Virus-like particles
Official title: {Virus-like particles}
A61K2039/5258 (Virus-like particles) appears on 1,040 US grants and 1,765 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,040
- Published applications
- 1,765
- Assignees
- 723
- Inventors
- 2,846
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 1 | 0 |
| 1998 | 6 | 0 |
| 1999 | 9 | 0 |
| 2000 | 6 | 0 |
| 2001 | 6 | 1 |
| 2002 | 7 | 13 |
| 2003 | 13 | 45 |
| 2004 | 11 | 53 |
| 2005 | 15 | 58 |
| 2006 | 16 | 55 |
| 2007 | 19 | 46 |
| 2008 | 31 | 53 |
| 2009 | 38 | 74 |
| 2010 | 36 | 80 |
| 2011 | 29 | 85 |
| 2012 | 29 | 67 |
| 2013 | 32 | 70 |
| 2014 | 42 | 75 |
| 2015 | 49 | 73 |
| 2016 | 61 | 76 |
| 2017 | 68 | 67 |
| 2018 | 70 | 72 |
| 2019 | 46 | 93 |
| 2020 | 66 | 84 |
| 2021 | 60 | 90 |
| 2022 | 59 | 90 |
| 2023 | 63 | 101 |
| 2024 | 63 | 99 |
| 2025 | 54 | 89 |
| 2026 | 30 | 56 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- C-terminus modified human papilloma virus type 6 L1 protein and use thereof22 Sep 2026US 12,741,016 B2Chinese Academy of Medical Sciences
- Virus-like particles containing CST1 protein and toxoplasma vaccine using same1 Sep 2026US 12,721,886 B2University-Industry Cooperation Group of Kyung Hee University
- Thermostable lipid nanoparticle and methods of use thereof4 Aug 2026US 12,697,308 B2Merck Sharp & Dohme Corp.
- Modified envelope protein of human immunodeficiency virus and use thereof4 Aug 2026US 12,697,383 B2Xiamen Innovax Biotech Co., Ltd.
- Method of producing an immunogenic composition7 Jul 2026US 12,673,094 B2Boehringer Ingelheim Animal Health USA Inc.
- Method for inducing an immune response8 Oct 2026US 2026/0306617 A1Acclarent, Inc.
- Programmably degradable hydrogels for functional molecular release1 Oct 2026US 2026/0294805 A1Georgia Tech Research Corporation
- Improved expression of surface-displayed antigens1 Oct 2026US 2026/0295030 A1Inprother Aps
- Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof1 Oct 2026US 2026/0295033 A1
- Recombinant expression vector for production of virus-like particle-based multivalent norovirus vaccine and manufacturing method therefor24 Sep 2026US 2026/0284173 A1Inthera Inc.
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Alphavirus vectors and virosomes with modified HIV genes for use in vaccines101US 6,783,939 B2AlphaVax, Inc. · 2004
- Hapten-carrier conjugates and uses thereof75US 6,932,971 B2Cytos Biotechnology AG · 2005
- Expression of HIV polypeptides and production of virus-like particles73US 6,602,705 B1Chiron Corporation · 2003
- Alphavirus replicons and helper constructs58US 7,442,381 B2AlphaVax, Inc. · 2008